Home › Compare › DTSRF vs ABBV
DTSRF yields 75.47% · ABBV yields 3.06%● Live data
📍 DTSRF pulled ahead of the other in Year 1
Combined, DTSRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DTSRF + ABBV for your $10,000?
The fund invests directly in ether that are held securely in cold storage while seeking to benefit from staking. Staking refers to the proof-of-stake consensus protocols that ensure transactions are properly recorded on a blockchain. The process allows owners of a cryptocurrency to validate block transactions through validators that verify the accuracy of recorded data. In return, validators are rewarded with digital assets. For the fund, rewards are paid in ether and will depend on the amount of ether staked. Staked ether serve as collateral that are locked in the network but are at risk of loss if validators fail to meet network rules. The fund manager selects and directs experienced sub-custodians as validators for staking activities. In addition, the fund manager has discretion in the amount of staked ether from the portfolio. The ETF does not intend to use derivatives or employ leverage to acquire ether. It may also hold cash, cash equivalents or other money market instruments.
Full DTSRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.